A mortality and morbidity study of refinery and petrochemical employees in Louisiana

S P Tsai, J K Wendt, K M Cardarelli, A E Fraser

Aims: To examine the mortality experience of 4221 employees from 1973 to 1999 and the illness absence patterns for 2203 employees from 1990 to 1999 of a chemical and refinery facility in Louisiana.

Methods: Mortality and illness absence data were extracted from the Shell Oil Company’s health surveillance system (HSS). The standardised mortality ratio was used as a measure of mortality risk. Morbidity frequency and duration of absence were calculated by age, sex, and four health risk factors (cigarette smoking, high blood pressure, hypercholesterolaemia, and obesity).

Results: Male employees experienced a significant deficit in mortality for all causes of death, all cancers, lung cancer, heart disease, and respiratory disease compared with the corresponding US population. Excess mortality along the Mississippi River was consistently lower than expected. The majority of employees had no illness absence of six days or longer during the 10 year study period. The loss of productivity (in terms of days of absence) was greater for employees with health risk factors. Ever smoking male employees had a 79% increase of heart disease and more than 50% higher rates of respiratory disease and musculoskeletal disorders compared to non-smokers. Smokers were absent 2.9 and 1.6 more days than non-smokers and ex-smokers, respectively.

Conclusions: Regardless of the comparison population, significantly fewer deaths were seen for all causes combined, all cancers, lung cancer, heart disease, or non-malignant respiratory disease. Illness absence rates and duration were higher among employees with health risk factors.

The study was conducted to assess the health status of employees at a refinery and chemical facility in Louisiana. Over the past 20 years, Louisiana has been a focus of public and state government concerns related to human health effects associated with potential occupational hazards and environmental pollution. The petrochemical industry has been cited as a major pollution source, especially along the Mississippi River of the Industrial Corridor area in southern Louisiana. In 1988, Greenpeace reported that “the devastating excess mortality along the Mississippi River and its significant association with increased levels of toxics warrants great concern, urgent action, and more research”. Since that time, several scientists have conducted research on cancer in Louisiana.1–7

The study population consisted of 4221 company refinery and chemical employees who worked more than six cumulative months before 31 December 1999, and who were actively employed as of 1 January 1973, or later, and pensioners who were alive as of 1 January 1973. An employee entered the follow up period on 1 January 1973, if he/she began employment at least six months before that date. Otherwise, he/she entered the study six months after the first
Main messages

- This study found no increased risk of mortality attributable to employment at this refinery and petrochemical facility. The favourable mortality finding is probably due to a combination of the healthy worker effect, the relative absence of risks related to employment at this facility, and the positive socioeconomic effects of continuing employment with its many benefits including greater access to medical care.
- The loss of productivity (in terms of days of absence) was greater for employees with selected health risk factors (smoking, high blood pressure, high cholesterol, and obesity). On an annual average, smokers were absent 2.9 and 1.6 more days than non-smokers and ex-smokers, respectively. Overweight employees were absent one day longer. Employees with high blood pressure were absent 6.2 days compared to 4 days for employees without hypertension. Employees with increased cholesterol also had a longer duration of absence than those with normal cholesterol levels (4.5 versus 4.2 days).

Policy implications

- This study has shown the usefulness of health surveillance data in studying an occupational cohort. Analysis of mortality and morbidity surveillance data can quickly identify areas of concern and be a useful prelude to the design of more specific occupational health studies.
- The findings of this study are useful in setting priorities for medical programmes and directing health promotion efforts and other prevention strategies.

day of employment. Person-years were accumulated from the entry date to the date of death or the study end date, whichever came first.

Vital status as of 31 December 1999 for each employee, including those who terminated employment for reasons other than retirement, was determined from a number of sources. Company records were supplemented with results of a data linkage search with the National Death Index (NDI), which has a demonstrated ability to ascertain 97% of deaths occurring since 1979. Additionally, we performed a data linkage search between company records and the Social Security Administration’s (SSA) Master Beneficiary Record file to identify any additional deaths that may have been missed by the NDI. Terminated employees not identified by the NDI search or the SSA search were assumed to be alive. Of those employees who were terminated before the inception of the study (31 December 1999), the date of retirement, the date of hire, or the date of entry to the date of death or the study end date, whichever came first.

The morbidity study population (n = 2203) consisted of all employees who worked at NMC from 1990 to 1999. This population was dynamic, with employees entering the observation period at different times, and some remaining for less than the entire period.

Morbidity data for this study were extracted from the morbidity section of the HSS, which includes all illness absence events of six work days or longer. Since records of absences originate from personnel and payroll systems, the absence reporting is virtually complete. Seventy-five percent of the morbidity reports had physician statements identifying the reason for the absence. The causes of morbidity were coded according to the ICD 9th Revision Clinical Modification. Only the primary cause was used in the analysis. Pregnancy and childbirth related absences were excluded.

Data for selected risk factors were also derived from the HSS, which contains all employee pre-placement and periodic examinations done since January 1978. The most current examination data for each employee were used; approximately 95% of these were completed since 1990. Smoking history from each examination was used to determine whether an employee was a current cigarette smoker. Increased cholesterol was defined as a value equal to or greater than 200 mg/dl. Raised blood pressures were those diastolic blood pressure readings equal to or greater than 90 mm Hg or systolic pressure readings equal to or greater than 140 mm Hg. Obesity was defined as body mass index (BMI = weight [in kg]/[height [in metres]]) greater than or equal to 27.2 for men and 26.9 for women. This value represents 20% more than the ideal body weight based on the National Institutes of Health Consensus Development Panel Recommendations.

The cancer morbidity experience of this population was compared with that of the State of Louisiana. In this comparison, a cancer incidence event was used as the health end point measure. Person-years at risk were calculated for each employee, beginning 1 January 1990, or the date of hire (whichever was later) and ending at the closing date of the study (31 December 1999), the date of retirement, the date of cancer diagnosis, or the date of termination/transfer (whichever was earlier). The expected numbers of cancer incidence cases were calculated from the age and cause specific cancer incidence rates of Louisiana for the years 1993–97. Age standardised incidence ratios (SIRs) for selected cancers were computed as the ratio of the observed to the expected number of new cancer cases during the study period.

RESULTS

Mortality

The study cohort included 4221 employees. The average age at entry into the cohort was 34.2 years. The total number of person-years of observation was 78 994; the subjects were followed for an average of 19.2 years for males and 15.8 years for females. Males comprised 85% of the total population. One third (33%) of the population was actively employed by the end of the study period, and retirees (n = 1334) accounted for 32% of the study population. The total number of deaths was 598. Two per cent of the cohort died while employed. Eighty-six per cent of the study population was still alive at the end of the study period. Blacks accounted for 12% of the total population, and whites, 88%. For purposes of statistical analysis, employees whose race could not be determined (5%) were included in the “white” category. Overall, more than a third
(35%) of the cohort members were hired before 1970, thus having follow up of up to 30 years. Female employees were fairly recent hires. The majority of female employees (60%) worked less than 10 years at NMC, while about three quarters of the males worked 10 years or longer. The average duration of employment at NMC was 20 years for males and 10 years for females.

Table 1 shows the observed deaths, expected deaths (based on US male mortality rates), SMRs, and their 95% CIs by selected causes of death for all male employees at Norco. A total of 580 deaths were observed, whereas 780 were expected, with a resultant SMR for all causes of 0.74 (95% CI 0.68 to 0.81). Similarly, there were 152 observed compared with 186 expected cancer deaths (SMR = 0.82, 95% CI 0.69 to 0.96). Statistically significant deficits in mortality were also observed for: cancer of the respiratory system (SMR = 0.70, 95% CI 0.51 to 0.93), including all cancer and heart disease. The mortality for diabetes mellitus was increased, with 16 observed compared with 9 expected deaths (SMR = 1.23). The mortality for all causes of death combined and for all cancer deaths was significantly lower (SMR = 0.77 and SMR = 0.83, respectively). The mortality for all lymphatic and haematopoietic tissue, and 0.45 (3 deaths) for Hodgkin's lymphoma (ICD code: 200 and 202).

Analysis was also conducted among employees hired since 1950. Results for this more recently employed subgroup were generally similar to the total group, although the SMR for all causes was lower (SMR = 0.62, 95% CI 0.55 to 0.71).

Cancers and certain chronic diseases may result after an extended period of occupational exposure. To assess the possible effect of a long duration of employment, a subgroup of male employees (n = 2605) with a minimum of 10 years of employment at this facility was also examined (table 2). This group contributed 61% of the person-years for the total cohort. The SMRs for all causes and all cancers were 0.75 (45 deaths for lung, 0.98 (17 deaths for prostate, 1.38 (6 deaths for kidney, 1.33 (6 deaths for brain, 0.64 (11 deaths for all lymphatic and haematopoietic tissue, and 0.45 (3 deaths for leukemia. There were 7 deaths due to non-Hodgkin's lymphoma (ICD code: 200 and 202), with 6.79 deaths expected (SMR = 1.03, 95% CI 0.41 to 2.12). The expected number of deaths for non-Hodgkin's lymphoma was not available from the OCMAP but was calculated based on the United States mortality rates specific to age, race, and calendar period. There was only one case of multiple myeloma in this group.

To examine regional effects on mortality, SMRs were also calculated for this subgroup using mortality rates for the State of Louisiana and the Industrial Corridor area proximate to the Norco complex (table 2). The use of regional rates increased the numbers of expected deaths by 6–11% for most of the major causes of death, including all cancer and heart disease.
The expected numbers of death from lung cancer (75.0 and 67.5) based on the State and Industrial Corridor rates were 24% and 12% greater than that of the USA (60.3), reflecting a generally higher mortality in Louisiana for this cancer during the study period. Similar patterns were also noted for pancreas cancer and diabetes mellitus, resulting in lower SMRs for these diseases when the State or Industrial Corridor rates were used as the comparison. Deaths from leukaemia were consistently lower in all three comparisons (five observed and five expected deaths), but this finding was not statistically significant. However, the number of observed episodes of morbidity at Norco was 8.5 years less than that of males.

A total of 2476 episodes of absence were reported during the 10 year study period (table 3), with 70 259 workdays lost, due to illness absence events in excess of five days (an average of 7026 days per year). This was equivalent to the absence from work of 2.2% of the average workforce (about 31 employees) each year at NMC during the study period, compared to 2.5% for all Shell manufacturing employees. This represents only 75% of the total days of absence since the study only included absences of six days or more. The frequency rates for morbidity generally increased with age, ranging from 7 absences per 100 person-years for those less than 30 years old to 30 absences per 100 person-years for those 60 and older. Female employees had similar rates to males for all age groups, except those aged 60+ where their rate was substantially lower than the male rate. The average duration of absence also increased with age, and was about the same for female and male employees (4.7 days per person versus 4.4 days per person annually). The 60+ years age group showed the greatest gender difference for average duration of absence (females 1.2 days, males 12.6 days).

### Table 2

<table>
<thead>
<tr>
<th>Cause of death (8th ICD revision)</th>
<th>OBS</th>
<th>EXP</th>
<th>SMR</th>
<th>EXP</th>
<th>SMR</th>
<th>EXP</th>
<th>SMR</th>
</tr>
</thead>
<tbody>
<tr>
<td>All causes of death (001–999)</td>
<td>541</td>
<td>704.2</td>
<td>0.77*</td>
<td>782.1</td>
<td>0.69*</td>
<td>725.1</td>
<td>0.75*</td>
</tr>
<tr>
<td>All malignant neoplasms (140–209)</td>
<td>145</td>
<td>174.7</td>
<td>0.83*</td>
<td>197.4</td>
<td>0.74*</td>
<td>184.3</td>
<td>0.79*</td>
</tr>
<tr>
<td>Digestive organs and peritoneum (150–159)</td>
<td>40</td>
<td>43.0</td>
<td>0.93</td>
<td>44.2</td>
<td>0.91</td>
<td>44.0</td>
<td>0.91</td>
</tr>
<tr>
<td>Stomach (151)</td>
<td>6</td>
<td>5.6</td>
<td>1.07</td>
<td>5.41</td>
<td>1.11</td>
<td>5.3</td>
<td>1.12</td>
</tr>
<tr>
<td>Large intestine (153)</td>
<td>15</td>
<td>13.7</td>
<td>0.83</td>
<td>15.6</td>
<td>0.83</td>
<td>16.5</td>
<td>0.79</td>
</tr>
<tr>
<td>Rectum (154)</td>
<td>4</td>
<td>3.3</td>
<td>1.22</td>
<td>2.7</td>
<td>1.46</td>
<td>2.4</td>
<td>1.70</td>
</tr>
<tr>
<td>Biliary passages and liver primary (155, 156)</td>
<td>2</td>
<td>4.2</td>
<td>0.47</td>
<td>5.1</td>
<td>0.39</td>
<td>5.1</td>
<td>0.39</td>
</tr>
<tr>
<td>Pancreas (157)</td>
<td>12</td>
<td>8.5</td>
<td>1.40</td>
<td>9.9</td>
<td>1.21</td>
<td>9.7</td>
<td>1.24</td>
</tr>
<tr>
<td>Respiratory system (160–163)</td>
<td>44</td>
<td>63.0</td>
<td>0.70*</td>
<td>78.2</td>
<td>0.56*</td>
<td>70.4</td>
<td>0.61*</td>
</tr>
<tr>
<td>Bronchus, trachea, long (162)</td>
<td>44</td>
<td>60.3</td>
<td>0.73*</td>
<td>75.0</td>
<td>0.59*</td>
<td>67.5</td>
<td>0.65*</td>
</tr>
<tr>
<td>Prostate (185)</td>
<td>18</td>
<td>17.6</td>
<td>1.02</td>
<td>17.7</td>
<td>1.02</td>
<td>15.3</td>
<td>1.17</td>
</tr>
<tr>
<td>Kidney (189, 189 1, 189 2)</td>
<td>5</td>
<td>4.3</td>
<td>1.17</td>
<td>4.7</td>
<td>1.06</td>
<td>4.7</td>
<td>1.07</td>
</tr>
<tr>
<td>Bladder and other urinary organs (188, 189 9)</td>
<td>5</td>
<td>4.9</td>
<td>1.01</td>
<td>4.6</td>
<td>1.09</td>
<td>5.0</td>
<td>0.99</td>
</tr>
<tr>
<td>Malignant melanoma of skin (172 0–172 4, 172 6–172 9)</td>
<td>0</td>
<td>2.6</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>Brain (191, 192)</td>
<td>5</td>
<td>4.1</td>
<td>1.22</td>
<td>4.1</td>
<td>1.23</td>
<td>4.4</td>
<td>1.14</td>
</tr>
<tr>
<td>All lymphatic and haematopoietic tissue (200–209)</td>
<td>14</td>
<td>16.2</td>
<td>0.87</td>
<td>17.1</td>
<td>0.82</td>
<td>17.6</td>
<td>0.79</td>
</tr>
<tr>
<td>Leukaemia and aleukaemia (204–207)</td>
<td>3</td>
<td>6.3</td>
<td>0.48</td>
<td>6.8</td>
<td>0.44</td>
<td>7.0</td>
<td>0.43</td>
</tr>
<tr>
<td>Diabetes mellitus (250)</td>
<td>16</td>
<td>13.1</td>
<td>1.23</td>
<td>17.2</td>
<td>0.93</td>
<td>15.8</td>
<td>1.01</td>
</tr>
<tr>
<td>Cerebrovascular disease (430–438)</td>
<td>43</td>
<td>41.6</td>
<td>1.03</td>
<td>46.6</td>
<td>0.92</td>
<td>38.3</td>
<td>1.12</td>
</tr>
<tr>
<td>All heart disease (390–8, 400 1, 400 9, 402, 404, 410–4, 420–4)</td>
<td>220</td>
<td>261.7</td>
<td>0.84*</td>
<td>290.7</td>
<td>0.76*</td>
<td>282.9</td>
<td>0.78*</td>
</tr>
<tr>
<td>Non-malignant respiratory disease (460–519)</td>
<td>21</td>
<td>60.9</td>
<td>0.35*</td>
<td>60.2</td>
<td>0.35*</td>
<td>52.8</td>
<td>0.40*</td>
</tr>
<tr>
<td>Cirrhosis of liver (571)</td>
<td>4</td>
<td>13.3</td>
<td>0.30*</td>
<td>11.7</td>
<td>0.34*</td>
<td>9.1</td>
<td>0.44</td>
</tr>
<tr>
<td>Accidents (800–949)</td>
<td>18</td>
<td>26.0</td>
<td>0.69</td>
<td>31.8</td>
<td>0.57*</td>
<td>27.1</td>
<td>0.67</td>
</tr>
<tr>
<td>All other causes of death</td>
<td>60</td>
<td>75.6</td>
<td>0.79</td>
<td>83.2</td>
<td>0.72*</td>
<td>76.4</td>
<td>0.79</td>
</tr>
</tbody>
</table>

†Expected number of deaths based on the United States male population, ICD revision in effect at the time of death.

*p < 0.05.

### Morbidity

Of the 2203 employees included in the study, 961 (44%) had at least one illness absence in excess of five days during the 10 year period. Overall, 15% of the employees (including 16% of males and 7% of females) had three or more absences, which accounts for two thirds (64%) of the total number of absences and three quarters (76%) of the total workdays lost. Female employees (n = 389) were an average of 8.7 years younger than males, and their average duration of employment at Norco was 8.5 years less than that of males.
musculoskeletal disorders and of endocrine system diseases (primarily diabetes) were notably higher than expected (observed versus expected: 264 versus 233, and 27 versus 20, respectively). For females, morbidity at Norco was 4% lower than that for Shell females overall (218 expected versus 228 observed). There were eight observed cancer cases (two lung, one thyroid, one breast, one colon, one tongue, one cervix, and one ovary) at Norco, with five expected. This difference was noted. For example, the observed cases of newly reported cancers for lung, leukaemia, and lymphoma among male employees, eight cases of newly diagnosed prostate cancer were reported. Using prostate cancer incidence rates for the State of Louisiana yielded 6.21 expected cases (SIR = 1.29, 95% CI 0.56 to 2.54). No common jobs were observed among these prostate cancer cases; job titles were purchasing assistant, engineering foreman, chemist, machinist, inspector, coking-hydroprocessing operator, pipefitter, and project coordinator. No increases of other specific cancer sites were noted. For example, the observed cases of newly reported cancers for lung, leukaemia, and lymphoma among male employees were lower than expected (5 versus 7.71, 1 versus 1.23, and 2 versus 3.06, respectively). Six malignant neoplasms were observed among females. The cases included lung cancer (n = 1), breast cancer (n = 1), colon cancer (n = 1), cervical squamous cell carcinoma (n = 1), and carcinoma of the tongue (n = 1). Job titles for the lung cancer cases were operator and office assistant, respectively.

DISCUSSION
This study examined the mortality and morbidity experience of NMC employees in Louisiana. The favourable mortality
experience of this cohort is comparable to what has been reported in other large petroleum and petrochemical populations. The lower overall mortality can be translated into longer life expectancy. Based on the mortality experience of either the total group or those who worked 10 years or more, the life expectancy at age 25 is estimated to be 3.2 years longer than the general US population. The magnitude of this relative advantage is equivalent to the potential gain in life expectancy if all cancers were eliminated as a cause of death in the US male population.

The favourable mortality findings and better life expectancy experienced by these employees is probably due to a combination of the "healthy worker effect," the relative absence of risks related to employment, and the positive socioeconomic effects of continuous employment with its many benefits including greater access to medical care. While it is difficult to quantify the impact of the healthy worker effect, studies have shown that the healthy worker effect decreased with length of time since entry into the study and generally disappeared after 15 years of follow up. The selection for "employability" (that is, fitness for duty) by the employer or self selection by the employee is probably the most significant factor for the healthy worker effect, and the impact of this selection is greater among employees with a short duration of employment. The selection process also tends to result in larger socioeconomic class differentials between the employed (with better qualifications) and unemployed (with poorer qualifications). To minimise the potential effect of the healthy worker effect in this study, a subgroup of male employees who worked for 10 years or longer was also examined. Mortality for all causes and all cancer of this group was similar to that of the total male cohort.

Although lung cancer mortality has been historically high among white men in Louisiana for several decades, there was a significantly decreased lung cancer death rate for the NMC period of observation. In addition, there was no increased leukemia mortality at this facility. Increased brain cancer mortality among chemical plant employees in Louisiana has been reported. In this study, the number of observed brain cancer cases was approximately the same as expected among male employees (6 versus 5 in the total male cohort, and 5 versus 4 among those working 10 or more years). Two of the cases had the majority of their work careers at the chemical plant, and four of the cases worked primarily at the refinery. A review of work histories for the brain cancer cases revealed no predominant pattern of job type or process operation. The average age at death for the brain cancer cases was 54 years, and the average duration of employment was 26 years (range 5–34 years). There were no new mesothelioma deaths found during the update period.

The sample size of this study for either all employees or potentially exposed employees is more than adequate to detect a 22% increase in mortality for all cancer, given a type I error of 0.05 and type II error of 0.20. Further, the sample size for the potentially exposed employees was able to detect a twofold increase in pancreas cancer, a 40% increase in lung cancer, an 80% increase in prostate and all lymphatic and haematopoietic tissue, and approximately a 2.5-fold increase of brain cancer and leukaemia, if they had existed.

The morbidity analyses of this study revealed that the small rates of illness absence among these employees were not statistically significant. The morbidity of this study is comparable to what has been noted by other researchers. Based on the morbidity experience of the entire group, the small percentage of employees with three or more absences over the 10 year period had a disproportionately large impact on the frequency and severity of morbidity. As expected, illness absence rates increased with increasing age. Similar observations have been noted by other researchers. The rates for older male workers (60 years and older) were fourfold those of younger males (less than 30 years of age). Similarly, average duration of absence was substantially longer among older employees (50+ years) than those less than 50 years of age.

No statistically significant excess of newly diagnosed malignant neoplasms during the 10 years from 1990 to 1999 was found for any cancer site. The increased prostate cancer morbidity (8 observed versus 6.21 expected) could be due to early detection of this disease through the company's prostate cancer screening programme, initiated in 1993 as part of the routine physical examination. In fact, four of the eight cases were identified as the result of the screening programme (three by positive PSA test and one through physical examination). Among the other four cases, one refused the rectal examination, one did not participate in the physical examination, one developed prostate cancer while on long term disability for peripheral vascular disease, and one developed the cancer between two physical examinations (1990 and 1993).

The health surveillance system does not include employees who died before 1 January 1973. The potential impact of excluding these subjects is not clear and could not be evaluated based on the available data for this study population. Because the cohort includes retirees known to be alive as of 1 January 1973, it could be argued that including these healthier long term survivors could dilute the observed mortality, particularly for cancer with shorter latency. To assess whether cancer of short latency was underestimated, additional analysis was conducted by excluding employees who retired and were alive as of 1 January 1973. Mortality for all causes (SMR = 0.64, 95% CI 0.57 to 0.71) was significantly lower than the total male cohort. The SMRs for all cancer combined (SMR 0.87, 116 observed deaths) as well as for specific cancers were generally similar to the overall group, for example, stomach (SMR = 1.00, 4 deaths), pancreas (SMR = 1.09, 7 deaths), lung (SMR = 0.79, 38 deaths), prostate (SMR = 1.29, 12 deaths), brain (SMR = 1.45, 6 deaths), all lymphatic and haematopoietic tissue (SMR = 0.90, 12 deaths), and leukaemia (SMR = 0.60, 3 deaths). It is not unexpected that the SMR for all heart disease was low (SMR = 0.69, 95% CI 0.57 to 0.85) which contributed to the lower overall mortality for this group. While it may have been informative to display morbidity and mortality rates stratified by personal exposure status, such data were not readily available for this surveillance study. The Norco manufacturing site does have an ongoing industrial hygiene monitoring programme for potentially hazardous agents. Monitoring is conducted for both key products and other materials used in connection with the manufacturing processes, and covers normal operations, maintenance, and special operations. Recent industrial hygiene monitoring data for NMC included 2806 personal samples for benzene. The measurements ranged from <0.001 ppm to 27.8 ppm, with 99% of the results below 0.0 ppm. The average was less than 0.1 ppm (standard deviation 1.0 ppm). It should be noted that the monitoring results represent potential rather than actual exposure when respiratory protection is worn, as is the case for certain work tasks with potential for significant exposure.

Illness absence in a working population is a complex phenomenon involving many factors. Personal characteristics related to morbidity frequency include age, gender, lifestyle, diet, alcohol use, smoking habits, and occupational factors. In this study, we found that persons with health risk factors such as smoking, increased blood pressure, raised cholesterol values, or obesity, had higher illness absence rates and duration of absences. These factors have been associated with increased morbidity. This study shows that certain subgroups of employees in this plant are more likely to experience illness absence events. Clearly, those individuals who have had more than one illness absence represent a group at high risk for additional episodes. Our ultimate goal is to develop medical strategies to maximise good health in employees and to minimise both the frequency and duration of illness absences. Careful return to work evaluations and promotion of smoking cessation, weight reduction, and blood pressure and cholesterol control for employees with multiple absences could produce long term
dividends. Prostate cancer screening, implemented at NMC in 1993, could have an impact on future prostate cancer mortality by providing early detection and allowing effective early treatment.

We will continue to monitor employee health by analysing mortality and morbidity surveillance data. By working closely with location staff, we can design customised studies to answer questions more definitively about employees’ health and its relation to other occupational or non-occupational factors.

************

Authors’ affiliations
S P Tsai, J K Wendt, K M Cordarelli, A E Fraser, Shell Oil Company, Corporate Health Department, Houston, Texas

RESEARCH
